Mirae Asset Healthcare Fund Direct Growth

Mirae Asset Healthcare Fund Direct Growth

NAV as on 28-03-2025

₹ 40.53

0.4%

1D

Inception Returns

22.8%

/yr

Historical NAV & Returns

Absolute

zero opening, trading, fund transfer fee
3073 people have invested ₹ 2.6Cr in Mirae Asset Healthcare Fund Direct Growth in the last three months

About Mirae Asset Healthcare Fund Direct Growth

Mirae Asset Healthcare Fund Direct Growth is an equity fund. This fund was started on 2 June, 2018. The fund is managed by Vrijesh Kasera. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Mirae Asset Healthcare Fund Direct Growth has ₹2441 Cr worth of assets under management (AUM) as on Feb 2025 and is more than category average.
  2. The fund has an expense ratio 0.5.

Returns

Mirae Asset Healthcare Fund Direct Growth has given a CAGR return of 22.78% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 18.97%, 19.77% and 30.98% respectively.

Holdings

Mirae Asset Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Industrial. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Divi's Laboratories Ltd, Lupin Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of Mirae Asset Healthcare Fund Direct Growth

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 99.00. Mirae Asset Healthcare Fund Direct Growth has no lock in period.

Mirae Asset Healthcare Fund Direct Growth Overview

Expense ratio0.52%
Benchmark
S&P BSE Healthcare PR
AUM₹2441 Cr
Inception Date2 June, 2018
Min Lumpsum/SIP₹5000/₹99
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
18.15%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

INDmoney Rank for Mirae Asset Healthcare Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
Lower expense ratio
img
Beats FD returns for both 3Y & 5Y duration
img
No bad points found for this fund.

Trailing Returns

as on (28-Mar-25)

Period
Mirae Asset Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
9.2%
7.3%
7.5%
3M
-6%
-4.6%
-7.6%
6M
-6.4%
-12%
-7.9%
1Y
19%
5.4%
16.4%
3Y
19.8%
12.7%
18.6%
5Y
31%
25.9%
28.1%

Fund Distribution

as on (28-Feb-25)

  • Equity 99.6%

  • Debt & Cash 0.4%

Mid cap
39%

Large cap
34.4%

Small cap
23.8%

Sector Allocation

Feb'25

Jan'25

Dec'24

Health
98.6%
Basic Materials
0.9%
Industrial
0.5%
All changes are between Dec'24 and Feb'25
Dec'24
Fund Returns
4.21%
Nifty 500
-2.02%
Parameters
Feb'25
Jan'25
Dec'24
AUM
₹ 2.4K Cr
₹ 2.7K Cr
₹ 2.9K Cr
  • AUM of the fund stands at 2.4K Cr as of Feb'25
  • AUM decreased by 211.1 Cr between Feb'25 and Jan'25
Top Stocks bought last month
Suven Pharmaceuticals Ltd's allocation increased from 3.54% to 4.43%
Suven Pharmaceuticals Ltd's allocation increased from 3.54% to 4.43%
Divi's Laboratories Ltd's allocation increased from 6.12% to 6.53%
Divi's Laboratories Ltd's allocation increased from 6.12% to 6.53%
Gland Pharma Ltd's allocation increased from 3.1% to 3.43%
Gland Pharma Ltd's allocation increased from 3.1% to 3.43%
Top Stocks sold last month
Aurobindo Pharma Ltd's allocation decreased from 7.23 % to 7.09 %
Aurobindo Pharma Ltd's allocation decreased from 7.23 % to 7.09 %
Glenmark Pharmaceuticals Ltd's allocation decreased from 5.55 % to 5.31 %
Glenmark Pharmaceuticals Ltd's allocation decreased from 5.55 % to 5.31 %
Dr Reddy's Laboratories Ltd's allocation decreased from 4.52 % to 4.42 %
Dr Reddy's Laboratories Ltd's allocation decreased from 4.52 % to 4.42 %
Mid Cap allocation has gone down from 39% to 39%
Mid Cap allocation has gone down from 39% to 39%
Large Cap allocation has gone down from 34.7% to 34.4%
Large Cap allocation has gone down from 34.7% to 34.4%
Small Cap allocation has gone up from 23.3% to 23.8%
Small Cap allocation has gone up from 23.3% to 23.8%
Cash allocation has gone up from 0.2% to 0.4%
Cash allocation has gone up from 0.2% to 0.4%

Top 3 Sectors in February were Health, Basic Materials & Industrial

Feb'25
Health
99%
Basic Materials
Industrial
Jan'25
Health
99%
Basic Materials
Industrial
Fund
Feb'25
Jan'25
Dec'24
No of Holdings
34
35
35
Top 5 Company Concentration
39.4%
38.8%
37.4%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (11.8%)
Sun Pharmaceuticals Industries Ltd (11.8%)
Sun Pharmaceuticals Industries Ltd (11.7%)
No of Sectors
3
3
2
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (98.6%)
Health (98.5%)
Health (98.6%)
Loading...
We are taking more time than usual
Vrijesh Kasera
Vrijesh Kasera
Fund Manager of Mirae Asset Healthcare Fund Direct Growth, since 2 July 2018
Fund House
Mirae Asset Investment Managers (India) Private Limited
Total Schemes
Total AUM
₹1.8L Cr
as on 28-Feb-2025
Address
Mirae Asset Investment Managers (India) Private Limited.,Unit No. 606, 6th Floor,,Windsor Bldg, Off CST Road,,Kalina, Santacruz (East), Mumbai - 400 098
Phone
91-22-22-6780300
Website
customercare@miraeasset.com

Mutual Fund Insights

Insights icon
Over the last 6 months, this fund has experienced a 11.5% drop in AUM moving from 2.75K Cr to 2.44K Cr.
Insights icon
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 31.15% return, outperforming this fund by 12.18%.
Insights icon
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 24.58% return, outperforming this fund by 4.81% per annum.
Insights icon
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 32.79% return, outperforming this fund by 1.81% per annum.
Insights icon
Over the last 15 months, this fund has decreased expense ratio by 10.3% moving from 0.58 to 0.52.
Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.52% which is lower than the category average expense ratio of 1.41%.

Mirae Asset Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 22.78% since inception which is more than its category average return of 17.1%
Fund Allocations

Fund Allocations

This fund has an allocation of 99.6% in Equity, 0% in Debt and 0.39% in Cash related instruments
AUM size ₹2441 Cr

AUM size ₹2441 Cr

This fund has AUM of ₹2441 Cr which is more than its category average of ₹ 1725 Cr
Expense Ratio 0.52%

Expense Ratio 0.52%

This fund has an expense ratio of 0.52% which is less than its category average expense ratio of 1.45%
Most Popular Comparisons
    • Mirae Asset Healthcare Fund
      Mirae Asset Healthcare Fund
      Vs
    • Nippon India Pharma Fund Direct Growth
      Nippon India Pharma Fund Direct Growth
    Compare
    • Mirae Asset Healthcare Fund
      Mirae Asset Healthcare Fund
      Vs
    • ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
      ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
    Compare
    • Mirae Asset Healthcare Fund
      Mirae Asset Healthcare Fund
      Vs
    • SBI Healthcare Opportunities Fund Direct Growth
      SBI Healthcare Opportunities Fund Direct Growth
    Compare
    • Mirae Asset Healthcare Fund
      Mirae Asset Healthcare Fund
      Vs
    • DSP Healthcare Fund Direct Growth
      DSP Healthcare Fund Direct Growth
    Compare
    • Mirae Asset Healthcare Fund
      Mirae Asset Healthcare Fund
      Vs
    • UTI Healthcare Fund Direct Growth
      UTI Healthcare Fund Direct Growth
    Compare

Frequently Asked Questions for Mirae Asset Healthcare Fund Direct Growth

The current NAV of Mirae Asset Healthcare Fund Direct Growth is ₹40.53 as on 28-Mar-2025.
Existing (Absolute + CAGR) as on 28-Mar-2025.
Mirae Asset Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
9.16%
9.16%
6 Month Returns
-6.42%
-6.42%
1 Year Returns
18.97%
18.97%
3 Years Returns
71.79%
19.77%
5 Years Returns
285.57%
30.98%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.52% as on March 2025
₹2441 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(11.84%), Cipla Ltd(7.6%), Aurobindo Pharma Ltd(7.09%), Divi's Laboratories Ltd(6.53%), Lupin Ltd(6.36%) as on March 2025
Health(98.24%), Basic Materials(0.86%), Industrial(0.5%) as on March 2025
The alpha ratio for the Mirae Asset Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Mirae Asset Healthcare Fund Direct Growth
0.54
-0.39
1.94
As on March 2025
The alpha for Mirae Asset Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Mirae Asset Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Mirae Asset Healthcare Fund Direct Growth
1.02
0.97
0.98
As on March 2025
The Beta for Mirae Asset Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Mirae Asset Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Mirae Asset Healthcare Fund Direct Growth
0.24
0.69
0.98
As on March 2025
The sharpe ratio for Mirae Asset Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Mirae Asset Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Mirae Asset Healthcare Fund Direct Growth
19.33
16.65
20.28
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.19 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Vrijesh Kasera is the fund manager of Mirae Asset Healthcare Fund Direct Growth
The Exit load of Mirae Asset Healthcare Fund Direct Growth is 1%